Study identification

EU PAS number

EUPAS5032

Study ID

5033

Official title and acronym

The healthcare costs associated with comorbidities of refractory asthma and systemic steroid exposure in the UK (Refractory Asthma & Steroid Exposure)

DARWIN EU® study

No

Study countries

United Kingdom

Study description

This study will use the UK’s Optimum Patient Care Research Database (OPCRD) to address a number of objectives relating to refractory asthma in the UK. The findings of the OPCRD evaluations will be compared to those of the British Thoracic Society's Difficult Asthma Registry morbidity prevalence data to help provide best morbidity prevalence estimates for the UK’s refractory asthma populations and to inform the development of models to estimate the burden of steroid-induced morbidity.The study will consist of two key phases:Phase 1: a cross-sectional matched cohort comparison of morbidity rates in patients with refractory asthma, those with well-controlled asthma and in non-asthmatic controls.Phase 2: a 7-year longitudinal matched cohort comparison of new incidence of morbidities in patients with refractory asthma, well-controlled asthma and non-asthmatic controls.

Study status

Ongoing
Research institutions and networks

Institutions

Networks

Respiratory Effectiveness Group (REG)
Belgium
Denmark
France
Germany
Greece
Hungary
Italy
Netherlands
Spain
Sweden
United Kingdom
First published:
04/06/2024
Network
ENCePP partner

Contact details

Heaney Liam

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Date of final study report

Planned:
Sources of funding
Other

More details on funding

University, Respiratory Effectiveness Group
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable